PDF
ePub
Citation
Print
Abstract
Purpose
E-cadherin is a tumor suppressor adhesion molecule that has an anti-invasive role and it is often considered as a useful marker for differentiating the lobular types from the ductal types of breast cancer. Yet the biological functions of E-cadherin in the invasive ductal types of breast cancers are unclear.
Methods
The E-cadherin expression was assessed immunohistochemically in 84 case of surgically resected invasive ductal carcinoma. Only the membranous expression of E-cadherin was considered and its expression was categorized as positive (>95% stained) or negative (<95% stained). The relationship between the E-cadherin expression and tumor size, the lymph node status, the histologic grade, the ER and PR status, The HER2/neu and p53 expressions was studied by performing prospective aspect.
Results
We analyzed 84 invasive ductal carcinomas for the E-cadherin expressions. Variable degrees of E-cadherin expression were noted in 79 cases and the complete absence of its expression was noted in 5 cases(5.9%) which showed all HER2/neu positive and p53 negative. Positive expression of E-cadherin was noted in 66cases(78.5%). Significant associations were found between the E-cadherin expression and the tumor size and the estrogen receptor status. The expression of E-cadherin was not found to be related to the lymph node status, histologic grade, the progesteron receptor status, the HER2/neu and p53 expressions.
Conclusion
We confirmed that there was a strong correlation between the negative membrane expressions of E-cadherin and the T-stages and a negative estrogen receptor status. E-cadherin immunostaining appears to have a minimal prognostic value and it can be efficiently used for determining tumor progression of invasive ductal carcinomas of the breast.
References
1. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin mediated cell-cell adhesion prevents invasiveness of carcinoma cells. J cell Biol. 1991. 113:173–185.
2. Pierceall WE, Woodard AS, Morrow JS, Rimm DI, Fearon ER. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene. 1995. 11:1319–1326.
3. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-cadherin as related to other prognostic factors and survival in breast cancer. J Pathol. 1994. 174:101–109.
4. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001. 115:85–98.
5. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am J Clin Pathol. 2002. 118:425–434.
6. Huiping C, Sigurgeirsdottir JR, Jonasson JG, Eiriksdottir G, Johannsdottir JT, Egilsson V, et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer. 1999. 81:1103–1110.
7. Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Br J Surg. 2002. 89:236–244.
8. Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol. 2003. 9:368–372.
9. Rakha RA, Rehim DA, Pinder SE, lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005. 46:685–693.
10. Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993. 143:1731–1742.
11. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996. 105:394–402.
12. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breas carcinoma. Am J Pathol. 1993. 142:987–993.
13. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-Cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Research. 1993. 53:1696–1701.
14. Brinck U, Jacobs S, Neuss M, Tory K, Rath W, Kulle B, et al. Diffuse growth pattern affects E-cadherin expression in invasive breast cancer. Anticancer Res. 2004. 24:2237–2242.
15. Gillett CE, Miles DW, Ryder K, Ryder K, Skilton D, Liebman RD, et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol. 2001. 193:433–441.
16. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer. 2001. 85:1958–1963.
17. Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J Pathol. 1999. 189:20–27.
18. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Dale ALB. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch. 1997. 432:317–321.
19. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000. 60:298–304.
20. Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J, et al. Assay of E-cadherin by ELLISA in human breast cancers. Eur J Cancer. 1997. 33:404–408.
21. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survivl in invasive ductal breast cancer. Clin Cancer Res. 2005. 11:4083–4089.
22. Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology. 2002. 41:127–133.
23. Asgeirsson KS, Jonasson JG, Tryggvadottir L, Olafsdottir K, Sigurgeirdottir JR, Ingvarsson S. Altered expression of E-cadherin in breast cancer pattern, mechanism and clinical significance. Eur J cancer. 2000. 36:1098–1106.
24. Kim JM, Kim TY, Song D, Kim SY, Back MJ, Lee MS, et al. Expression of E-cadherin and clinical correlation in patients with breast carcinoma. J Korean Breast Cancer Soc. 2004. 7:148–153.
XML Download